RVTY - Revvity • Financials

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
01/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
01/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
01/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
01/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	2,751	740	-	25%	5.6	7,873	9%	1,575	2.1	50	-81	-947	-32	-389	-35	5%	0.26%
12/2024	2,755	781	-	10%	2.2	7,667	4%	1,987	2.6	590	-87	-1,128	504	-370	-34	13%	0.25%
12/2025	2,856	767	-	8%	2.1	7,250	3%	1,711	2.2	560	-74	-858	487	-821	-33	14%	0.29%

To see all financials—including updated, you must be Premium.